Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Cancer Diagnostics"

00:38 EDT 19th April 2014 | BioPortfolio

Original Source: Lab21 Launches New Lung Cancer Diagnostic Service

Cambridge, UK – 16 February 2012 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has launched a new Companion Diagnostic testing service for non-small cell lung cancer patients. The EML4-ALK companion diagnostic test for translocations in the ALK gene will allow physicians to select lung cancer patients likely to respond to ALK inhibitor therapy. The test uses proprietary PCR technology and will be performed in Lab21’s accredited laboratories in...

Matching Channels


Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

Vulvar Cancer

Nasopharyngeal Cancer

Urethral Cancer

Laryngeal Cancer

Matching News

Next-Generation Sequencing and Cancer Diagnostics

This commentary explores the latest developments in next-generation sequencing technologies, and their potential impact on cancer diagnostics. What challenges remain? Expert Review of Molecular Diag...

Qiagen, Exosome Diagnostics to develop diagnostics for cancer

Qiagen, a Netherlands-based holding company, has expanded its strategic partnership with Exosome Diagnostics to develop a first-in-class, non-invasive molecular in-vitro diagnostics for use in diagnos...

Qiagen, Exosome Diagnostics expand partnership to develop diagnostics for lung cancer

Netherlands-based Qgen and US-based Exosome Diagnostics have announced an expansion of their strategic partnership for developing non-invasive molecular in-vitro diagnostics for key genetic biomarkers...

Cancer therapy and cancer diagnostics

Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones,...

PointMan enriches low-level DNA mutations from whole blood

Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment EKF Diagnostics, the global in vitro diagnostics business, an...

Molecular Diagnostics in Cancer Testing - TMRMDC13-1101

Recently added to the BioPortfolio report store, Molecular Diagnostics in Cancer Testing - TMRMDC13-1101 is a new report from TriMark Publications published on 2013-10-31. This 232-page report is ava...

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unn...

New biomarkers improve prostate cancer diagnostics

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely – thereby helping avoid u...

Matching PubMed Articles

Structured diagnostics and therapy of the CUP syndrome.

In the majority of cases, patients with cancer of unknown primary (CUP) have a poor prognosis with no prospect of being cured. Hence, a reasonable focus of diagnostics on its essential targets seems a...

From the guest editor: into the era of personalized cancer diagnostics.

Anticipating Precision Medicine's Future.

Instead of investing in technologies to test a few genes at a time, researchers and regulators should plan for the routine use whole-genome sequencing in the diagnosis of cancer, according to speakers...

Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment.

Aptamers are single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) oligonucleotides, which are able to bind their target with high selectivity and affinity. Owing to their multiple tal...

Cancer of unknown primary : Epidemiology and pathogenesis.

The term cancer of unknown primary (CUP) describes by definition epithelial malignancies for which no primary tumor can be found after primary diagnostics have been performed.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement